- Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated
- Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
On 6ix: 6ix.com/news/rapport-announces-positive-topline-results-phase-2a-clinical-trial-rap-219-patients
Rapport Therapeutics, Inc. on 6ix
In the deck
Story so far
Earlier from Rapport Therapeutics
- Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
- Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
- Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
- Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
- Rapport Therapeutics to Host 2025 Investor and Analyst Day
Later from Rapport Therapeutics
- Rapport Announces Pricing of Public Offering of Common Stock
- Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
- Rapport Therapeutics to Participate in Upcoming Investor Conferences
- Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
- Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Follow Rapport Therapeutics into a list and get an email when it puts out news.
Follow Rapport Therapeutics